Nanobiotix Yönetim

Yönetim kriter kontrolleri 1/4

Nanobiotix CEO'su Laurent Levy, Mar2003 tarihinde atandı, in görev süresi 21.83 yıldır. in toplam yıllık tazminatı € 3.40M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.1% maaş ve 87.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.4% ine doğrudan sahiptir ve bu hisseler € 3.55M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.5 yıl ve 2.2 yıldır.

Anahtar bilgiler

Laurent Levy

İcra Kurulu Başkanı

€3.4m

Toplam tazminat

CEO maaş yüzdesi	12.1%
CEO görev süresi	21.8yrs
CEO sahipliği	2.4%
Yönetim ortalama görev süresi	5.5yrs
Yönetim Kurulu ortalama görev süresi	2.2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Laurent Levy'un ücretlendirmesi Nanobiotix'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-€33m
Mar 31 2024	n/a	n/a	-€37m
Dec 31 2023	€3m	€411k	-€40m
Sep 30 2023	n/a	n/a	-€49m
Jun 30 2023	n/a	n/a	-€59m
Mar 31 2023	n/a	n/a	-€58m
Dec 31 2022	€1m	€380k	-€57m
Sep 30 2022	n/a	n/a	-€50m
Jun 30 2022	n/a	n/a	-€43m
Mar 31 2022	n/a	n/a	-€45m
Dec 31 2021	€4m	€380k	-€47m
Sep 30 2021	n/a	n/a	-€45m
Jun 30 2021	n/a	n/a	-€43m
Mar 31 2021	n/a	n/a	-€39m
Dec 31 2020	€818k	€330k	-€34m
Sep 30 2020	n/a	n/a	-€41m
Jun 30 2020	n/a	n/a	-€48m
Mar 31 2020	n/a	n/a	-€49m
Dec 31 2019	€2m	€330k	-€51m
Sep 30 2019	n/a	n/a	-€46m
Jun 30 2019	n/a	n/a	-€42m
Mar 31 2019	n/a	n/a	-€36m
Dec 31 2018	€1m	€300k	-€30m

Tazminat ve Piyasa: Laurent 'nin toplam tazminatı ($USD 3.53M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 891.39K ).

Tazminat ve Kazançlar: Laurent şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Laurent Levy (51 yo)

21.8yrs

Görev süresi

€3,396,084

Tazminat

Mr. Laurent Lévy, Ph.D. has been the President of the Executive Board at Nanobiotix S.A. since May 27, 2004 and its Chief Executive Officer since March 2003. Mr. Lévy has a thorough understanding of the te...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Laurent Levy	Co-Founder	21.8yrs	€3.40m	2.4% € 3.5m
Bart Van Rhijn	Chief Financial & Business Officer and Member of Executive Board	3.6yrs	€1.50m	0% € 0
Anne-Juliette Hermant	Chief People Officer & Member of Executive Board	5.5yrs	€801.96k	0.30% € 436.0k
Louis Kayitalire	Chief Medical Officer	1.3yrs	€500.80k	Veri yok
Earl Bergey	Co-Founder	22yrs	Veri yok	Veri yok
Craig West	Senior Vice President of Investor Relations	no data	Veri yok	Veri yok
Brandon Owens	VP of Strategic Marketing & Corporate Communication	no data	Veri yok	Veri yok
Margaret Galluzzi	VP & Global Head of Clinical Operations	6yrs	Veri yok	Veri yok
Leonard Farber	Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board	2.9yrs	Veri yok	Veri yok

5.5yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: 5NR 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Leonard Farber	Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board	no data	Veri yok	Veri yok
Enno Spillner	Independent Member of Supervisory Board	10.6yrs	€50.00k	Veri yok
Gary Phillips	Independent Chairman of Supervisory board	3.7yrs	€63.00k	Veri yok
Silvia Formenti	Member of Scientific Advisory Board	2.2yrs	Veri yok	Veri yok
Alain Herrera	Independent Member of Supervisory Board	11.6yrs	€35.00k	Veri yok
Anne-Marie Graffin	Independent Vice Chairman of the Supervisory Board	11.1yrs	€42.00k	Veri yok
Hisham Mehanna	Member of Scientific Advisory Board	2.2yrs	Veri yok	Veri yok
Stephane Champiat	Member of Scientific Advisory Board	2.2yrs	Veri yok	Veri yok
Jean Bourhis	Member of Scientific Advisory Board	2.2yrs	Veri yok	Veri yok
Thierry Baere	Member of Scientific Advisory Board	2.2yrs	Veri yok	Veri yok
Christophe Tourneau	Member of Scientific Advisory Board	2.2yrs	Veri yok	Veri yok
Nancy Lee	Member of Scientific Advisory Board	2.2yrs	Veri yok	Veri yok

2.2yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 5NR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.2 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/06 03:32
Gün Sonu Hisse Fiyatı	2025/01/06 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Nanobiotix S.A. 14 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Mickael Chane-Du	Bryan Garnier & Co
Philippa Gardner	Edison Investment Research
Jonathan Miller	Evercore ISI

Nanobiotix Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Recent updates

First half 2024 earnings released: €0.46 loss per share (vs €0.80 loss in 1H 2023)

New minor risk - Share price stability

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

New minor risk - Profitability

Forecast to breakeven in 2026

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

New minor risk - Financial position

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

New minor risk - Shareholder dilution

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

No longer forecast to breakeven

NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

Forecast to breakeven in 2024

NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer

NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Forecast to breakeven in 2024

NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT

Full year 2021 earnings released: €1.35 loss per share (vs €1.38 loss in FY 2020)

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

First half 2021 earnings released: €0.88 loss per share (vs €0.91 loss in 1H 2020)

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting

Full year 2020 earnings released: €1.38 loss per share (vs €2.35 loss in FY 2019)

Full year 2020 earnings released

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

NANOBIOTIX Announces Positive New Preclinical Data Investigating First-In-Class Radioenhancer NBTXR3

Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021

Nanobiotix Announces First Patient Injected with NBTXR3 in Esophageal Cancer

NANOBIOTIX Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021

New 90-day high: €15.32

New 90-day high: €14.10

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $99 million.

Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces Positive New Pre-Clinical Data Suggesting Radioenhancer NBTXR3 Could Have A Significant Impact in Immunotherapy

Nanobiotix Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3

New 90-day low: €5.60

Nanobiotix Provides Updates on Global Clinical Development Plan for First-In-Class Radioenhancer Nbtxr3 At Astro 2020

NANOBIOTIX Announces First Patient Injected with Nbtxr3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials from U.S. FDA

New 90-day low: €6.36

New 90-day low - €6.67

First half earnings released

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of €20.13 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi